

Raptor Pharmaceutical Corp  
 Form 4  
 September 18, 2014

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 STARR CHRISTOPHER M

(Last) (First) (Middle)

C/O RAPTOR  
 PHARMACEUTICAL CORP., 7  
 HAMILTON LANDING, SUITE  
 100

(Street)

NOVATO, CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
 Raptor Pharmaceutical Corp [RPTP]

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 09/16/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 Chief Executive Officer

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code |   |        |           | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|---------------------|---|--------|-----------|---|--|-----------------------------------|
|                                 |                                      |  | Code                | V | Amount | Price     |   |  |                                   |
| Common Stock                    | 09/16/2014 <sup>(1)</sup>            |  | M                   |   | 2,088  | A \$ 2.02 | 701,458   | D  |                                   |
| Common Stock                    | 09/16/2014 <sup>(1)</sup>            |  | M                   |   | 835    | A \$ 2.02 | 702,293   | D  |                                   |
| Common Stock                    | 09/16/2014 <sup>(1)</sup>            |  | M                   |   | 957    | A \$ 2.97 | 703,250   | D  |                                   |
| Common Stock                    | 09/16/2014 <sup>(1)</sup>            |  | M                   |   | 29,016 | A \$ 2.97 | 732,266   | D  |                                   |
|                                 | 09/16/2014 <sup>(1)</sup>            |  | S                   |   | 32,896 | D         | 699,370   | D  |                                   |

Edgar Filing: Raptor Pharmaceutical Corp - Form 4

Common Stock \$ 10.5968  
(3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Stock options (right to buy)               | \$ 2.02  | 09/16/2014 <sup>(1)</sup>            |  | M                              | 2,088   | <sup>(2)</sup> 03/09/2020                                | Common Stock  | 2,088                         |
| Stock options (right to buy)               | \$ 2.02  | 09/16/2014 <sup>(1)</sup>            |  | M                              | 835   | <sup>(2)</sup> 03/09/2020                                | Common Stock  | 835                           |
| Stock options (right to buy)               | \$ 2.97  | 09/16/2014 <sup>(1)</sup>            |  | M                              | 957   | <sup>(2)</sup> 10/11/2020                                | Common Stock  | 957                           |
| Stock options (right to buy)               | \$ 2.97  | 09/16/2014 <sup>(1)</sup>            |  | M                              | 29,016  | <sup>(2)</sup> 10/11/2020                                | Common Stock  | 29,016                        |

## Reporting Owners

| Reporting Owner Name / Address                         | Relationships |           |                         |       |
|--|---------------|-----------|-------------------------|-------|
|  | Director      | 10% Owner | Officer                 | Other |
| STARR CHRISTOPHER M<br>C/O RAPTOR PHARMACEUTICAL CORP. | X             |           | Chief Executive Officer |       |

7 HAMILTON LANDING, SUITE 100  
NOVATO, CA 94949

## Signatures

/s/ Mark Jones, Raptor Pharmaceutical Corp.,  
Attorney-in-Fact

09/18/2014

\_\_\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 20, 2014.
- (2) Fully vested and exercisable.

- This transaction was executed in multiple trades at prices ranging from \$10.40 to 10.81. The price reported above reflects the weighted
- (3) average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.